Novel therapies for familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol and premature cardiovascular disease.
• Standard lipid-lowering therapies (LLT) often fail to achieve target LDL-C levels in FH patients.
• Effective management of FH is crucial to prevent atherosclerotic cardiovascular events.

Purpose of the Study:

• To review current and emerging novel therapeutic options for familial hypercholesterolemia.
• To assess the efficacy of new treatments in lowering LDL cholesterol in FH patients.
• To highlight advancements in managing this genetic lipid disorder.

Main Methods:

• Review of current literature on novel FH therapies.
• Analysis of clinical trial data for PCSK9 inhibitors, inclisiran, and evinacumab.
• Evaluation of treatment efficacy based on LDL-C reduction and achievement of target levels.

Main Results:

• PCSK9 inhibitors reduce LDL-C by up to 60% in heterozygous FH (HeFH) and 35% in homozygous FH (HoFH).
• Inclisiran offers a sustained LDL-C reduction of nearly 50% in HeFH by reducing PCSK9 production.
• Evinacumab lowers LDL-C by 50% independently of LDL receptor activity, offering an alternative mechanism.

Conclusions:

• Novel therapies significantly improve LDL-C reduction in FH patients.
• Most patients with HeFH and a substantial proportion of HoFH patients can achieve target LDL-C with new treatments.
• Advancements in FH therapeutics offer improved outcomes and disease management.